New cream targets skin lymphoma without steroids
NCT ID NCT07658924
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a cream called benvitimod (tapinarof) for people with cutaneous T-cell lymphoma, a rare skin cancer that causes red patches and itching. The cream is non-steroidal and works by targeting a specific receptor in skin cells. About 35 adults with the disease will apply the cream to one skin lesion and a placebo to another, allowing a direct comparison. Researchers will measure changes in lesion severity and itching over 24 weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Benvitimod (Tapinarof) cream
What this could lead to
If effective, this cream could offer a new, non-steroidal option to control skin lesions and itching in early-stage cutaneous T-cell lymphoma.
What could go wrong
This is a small, early-phase trial with only 35 participants. The cream may not work better than placebo, and side effects like skin irritation are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CUTANEOUS T CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.